| Name | Title | Contact Details |
|---|
Ascend empowers entrepreneurial CPAs to reach their goals with an innovative growth model that brings their firms into the new age. Backed by private equity from people-focused Alpine Investors, Ascend is building a modern platform for regional accounting firms that enables them to stay independent while accessing the resources of a large CPA firm to help them grow. Ascend provides access to growth capital, robust talent acquisition, best-of-breed technology, a catalytic leadership system, shared back-office services, and modernized equity incentives so that firms can surmount todays industry challenges and reach their full potential. Founded in January 2023, the company attained revenues sufficient to qualify it as a Top 100 U.S. accounting firm within six months of operation.
Built from the ground up to support computationally intensive workloads, we provide the best tools for creators leveraging powerful accelerated hardware. A traditionally costly and scarce resource, GPU compute options from mono-lithic cloud providers are extremely limited. CoreWeave provides the industry`s widest range of GPU options, allowing you to pick the perfect GPU for your use case. Thousands of GPUs are ready and waiting.
Lindsey Management Co., Inc. (LMC) is a leading property management firm located in Fayetteville, Arkansas. Founded in 1985, it has become the largest company in Arkansas specializing in multi-family housing and has expanded its services into neighboring states such as Alabama, Kansas, Mississippi, Missouri, and Oklahoma. LMC provides a wide range of property management services, primarily focusing on multi-family housing. The company manages over 140 apartment communities, totaling more than 32,000 apartments and executive suites. Additionally, LMC oversees numerous golf courses, including five Par 3 courses, five executive courses, thirteen regular courses, and sixteen 18-hole courses across Arkansas and surrounding states. Its services include leasing, maintenance, and customer support for both residential and recreational properties.
CAC Group operates in two distinct sectors. The first entity, CAC Group (Insurance & Advisory Services), is a prominent insurance broker and advisor. They specialize in customized solutions for insurance and capital markets, offering advisory and placement services for complex risk management. They also provide bespoke financial solutions through CAC Capital, focusing on private finance and structured offerings. In August 2024, they launched a new brand identity to reflect their expanded capabilities. The second entity, CAC Holdings Corporation, is a Japanese IT services conglomerate established in 1966. With 23 subsidiaries worldwide, it provides IT system construction, operation, and strategic consulting for enterprises. The company is led by President and CEO Ryota Nishimori and has a consolidated workforce of 4,653 employees. As of December 2024, CAC Holdings reported a capital of ¥3.7 billion and consolidated sales of ¥52.06 billion.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.